Use of inhibitor of FLJ protein, for treatment and prevention of e.g. cancer, diabetic retinopathy or arthritis, also new protein, nucleic acid and their inhibitors

• Main Authors: SCHWEIGHOFFER FABIEN, VALENTIN EMMANUEL, PETIT SILVERE
• Format: Patent
• Language: English; French
• Published: 26.03.2004
• Edition: 7
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; ENZYMOLOGY; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; ORGANIC CHEMISTRY; PEPTIDES; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; VINEGAR; WINE

Use of an inhibitor (I) of the FLJ protein to prepare a composition for (i) treating or preventing cancers, including metastatic spread; (ii) inhibiting angiogenesis; (iii) treating diabetic retinopathy, osteoarthritis, rheumatoid arthritis, psoriasis and disorders of delayed healing; (iv) regulating vascular or paracellular permeability or (v) preserving or restoring tissue integrity. Independent claims are also included for: (1) antibodies (Ab) specific for FLJ protein; (2) antisense nucleic acid that inhibits transcription of the FLJ gene or translation of the corresponding mRNA; (3) cytotoxic ligand specific for FLJ protein containing cytotoxic and FLJ-specific segments; (4) human FLJ having a 226 amino acid sequence (2), reproduced; (5) nucleic acid probes for detecting the FLJ gene (or its mRNA) by selective hybridization, comprising at least part of a 1871 bp sequence (1), reproduced; (6) primer comprising a single-stranded nucleic acid of 5-60 nucleotides complementary to part of (1) or its complement; (7) detecting a disease (or predisposition), also for monitoring and staging, by determining the amount, relative or absolute, or distribution of FLJ protein, its expression, altered forms or the corresponding gene or mRNA; (8) selecting, screening, characterizing, optimizing or producing active compounds (A) by determining their capacity to interact with FLJ protein or to modify its expression or activity; (9) cloning and expression vector containing nucleic acid that encodes FLJ protein; and (10) recombinant cell containing the vector of (9) or nucleic acid that encodes and expresses FLJ protein. La présente demande concerne le domaine de la biologie et de la santé. Elle concerne plus particulièrement l'identification et la caractérisation fonctionnelle d'une nouvelle protéine impliquée dans les mécanismes de perméabilité vasculaire, d'adhésion cellulaire et d'angiogénèse, ainsi que l'utilisation de cette protéine comme cible thérapeutique, diagnostique ou de criblage. Elle porte également sur des outils utilisables pour la mise en oeuvre de méthodes thérapeutiques, diagnostiques ou de criblage, comme notamment des sondes, anticorps, vecteurs, cellules recombinantes, etc. L'invention est particulièrement utile pour la préparation de composés pharmaceutiques dans le domaine des cancers, de l'angiogenèse, des maladies inflammatoires ou des altérations tissulaires.